Phase II trial of amsacrine in patients with multiple myeloma.
Seventy-four previously treated patients with multiple myeloma were treated with Amsacrine (m-AMSA) 120 mg/m2 every 3 weeks. A good response was observed in two patients (3%), and improvement was seen in three patients (4%). Severe toxicity was observed in 33% of patients who received three or more courses of treatment. This dose and schedule of m-AMSA in multiple myeloma is usually ineffective.
Greipp
P R
PR
Mayo Clinic, Rochester, Minnesota.
Coleman
M
M
Anderson
K
K
McIntyre
O R
OR
D000328:Adult; D000368:Aged; D000677:Amsacrine / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*
D000677:Amsacrine